Carlsmed (CARL) Competitors

66.4% of Alphatec shares are owned by institutional investors. 13.5% of Alphatec shares are owned by insiders. Comparatively, 12.9% of Carlsmed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Alphatec currently has a consensus target price of $17.40, suggesting a potential upside of 69.76%. Carlsmed has a consensus target price of $19.25, suggesting a potential upside of 33.87%. Given Alphatec's stronger consensus rating and higher possible upside, equities analysts clearly believe Alphatec is more favorable than Carlsmed.

Alphatec has a net margin of -13.49% compared to Carlsmed's net margin of -57.42%. Carlsmed's return on equity of -38.06% beat Alphatec's return on equity.

Carlsmed has lower revenue, but higher earnings than Alphatec. Alphatec is trading at a lower price-to-earnings ratio than Carlsmed, indicating that it is currently the more affordable of the two stocks.

Alphatec has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market. Comparatively, Carlsmed has a beta of 2.09, meaning that its share price is 109% more volatile than the broader market.

In the previous week, Carlsmed had 4 more articles in the media than Alphatec. MarketBeat recorded 8 mentions for Carlsmed and 4 mentions for Alphatec. Alphatec's average media sentiment score of 0.42 beat Carlsmed's score of 0.31 indicating that Alphatec is being referred to more favorably in the media.

97.7% of Omnicell shares are owned by institutional investors. 2.9% of Omnicell shares are owned by company insiders. Comparatively, 12.9% of Carlsmed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Omnicell has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market. Comparatively, Carlsmed has a beta of 2.09, indicating that its stock price is 109% more volatile than the broader market.

Omnicell has a net margin of 3.13% compared to Carlsmed's net margin of -57.42%. Omnicell's return on equity of 5.66% beat Carlsmed's return on equity.

Omnicell has higher revenue and earnings than Carlsmed. Carlsmed is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Omnicell currently has a consensus price target of $57.86, suggesting a potential upside of 64.32%. Carlsmed has a consensus price target of $19.25, suggesting a potential upside of 33.87%. Given Omnicell's stronger consensus rating and higher probable upside, equities research analysts clearly believe Omnicell is more favorable than Carlsmed.

In the previous week, Carlsmed had 3 more articles in the media than Omnicell. MarketBeat recorded 8 mentions for Carlsmed and 5 mentions for Omnicell. Omnicell's average media sentiment score of 0.33 beat Carlsmed's score of 0.31 indicating that Omnicell is being referred to more favorably in the media.

CONMED has a net margin of 4.12% compared to Carlsmed's net margin of -57.42%. CONMED's return on equity of 14.31% beat Carlsmed's return on equity.

Carlsmed has a beta of 2.09, suggesting that its share price is 109% more volatile than the broader market. Comparatively, CONMED has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market.

In the previous week, Carlsmed had 4 more articles in the media than CONMED. MarketBeat recorded 8 mentions for Carlsmed and 4 mentions for CONMED. CONMED's average media sentiment score of 0.38 beat Carlsmed's score of 0.31 indicating that CONMED is being referred to more favorably in the news media.

Carlsmed presently has a consensus price target of $19.25, indicating a potential upside of 33.87%. CONMED has a consensus price target of $41.40, indicating a potential downside of 6.38%. Given Carlsmed's stronger consensus rating and higher possible upside, equities analysts clearly believe Carlsmed is more favorable than CONMED.

CONMED has higher revenue and earnings than Carlsmed. Carlsmed is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

Carlsmed presently has a consensus price target of $19.25, indicating a potential upside of 33.87%. Alpha Tau Medical has a consensus price target of $15.40, indicating a potential upside of 8.07%. Given Carlsmed's stronger consensus rating and higher probable upside, equities research analysts clearly believe Carlsmed is more favorable than Alpha Tau Medical.

In the previous week, Carlsmed had 6 more articles in the media than Alpha Tau Medical. MarketBeat recorded 8 mentions for Carlsmed and 2 mentions for Alpha Tau Medical. Carlsmed's average media sentiment score of 0.31 beat Alpha Tau Medical's score of 0.05 indicating that Carlsmed is being referred to more favorably in the media.

2.7% of Alpha Tau Medical shares are held by institutional investors. 12.9% of Carlsmed shares are held by company insiders. Comparatively, 39.5% of Alpha Tau Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Carlsmed has higher revenue and earnings than Alpha Tau Medical. Alpha Tau Medical is trading at a lower price-to-earnings ratio than Carlsmed, indicating that it is currently the more affordable of the two stocks.

Carlsmed has a beta of 2.09, suggesting that its share price is 109% more volatile than the broader market. Comparatively, Alpha Tau Medical has a beta of 1.22, suggesting that its share price is 22% more volatile than the broader market.

Alpha Tau Medical has a net margin of 0.00% compared to Carlsmed's net margin of -57.42%. Carlsmed's return on equity of -38.06% beat Alpha Tau Medical's return on equity.